Latest Capital Raise News

Anteris Technologies Global Corp. has entered a material definitive agreement to raise approximately $320 million through a public offering and a strategic private placement with Medtronic’s subsidiary. The capital will support clinical trials and manufacturing expansion for its innovative heart valve technology.

Albright Metals has completed a key diamond drilling program at its Golden Pike Project in Canada and initiated antimony drilling at Bond Road, supported by a successful $1.98 million capital raise.

Euroz Hartleys reports a striking 121% jump in net profit for H1 FY2026, driven by booming equity capital markets activity and rising advisory fees. The company also lifts its interim dividend, signalling confidence amid cyclical market conditions.

EPX Limited has successfully raised nearly $295,000 through a Security Purchase Plan, supporting its recent acquisition of Wattwatchers and positioning the company for further expansion.

DMC Mining Limited will be delisted from the ASX on 27 January 2026 following a two-year suspension, but the company remains committed to relisting pending key exploration licences in Guinea.

Auravelle Metals has reported significant high-grade gold intersections at its Sheoak Prospect in South Australia, extending the gold trend beyond 600 metres and identifying new targets at Sheoak East. Meanwhile, early drilling at its Crown Gold Project in Western Australia confirms extensive gold anomalism, supported by a successful $2.5 million capital raise to fund ongoing exploration.

Sky Metals has launched a major drilling campaign at its Tallebung Tin Project, aiming to expand high-grade resources and update its Mineral Resource Estimate. Meanwhile, a metallurgical breakthrough at Doradilla confirms its potential as a second key tin asset.

Ballard Mining has raised $61 million through a well-supported placement to fund an aggressive drilling program and early development works at its Mt Ida Gold Project, positioning the company for a Final Investment Decision.

Nyrada Inc. has secured ethics approval to launch a Phase IIa clinical trial for its heart attack drug Xolatryp®, with patient recruitment set for March 2026. The company maintains a solid cash position of AU$7.12 million as it expands its research into oncology.

Bounty Oil & Gas has announced a significant board renewal, including the appointment of Kane Marshall as Chairman and the retirement of long-serving CEO Philip Kelso. These leadership changes mark a new chapter as the company pursues growth in its Australian oil and gas assets.

American Tungsten & Antimony Ltd is progressing its Nasdaq listing plans with a confidential SEC filing expected in March 2026 and has appointed Deutsche Bank as ADR depositary alongside a new CFO to support growth.

Venus Metals Corporation progresses its Sandstone Bellchambers gold project with a new mining lease and exploration targets, while extending its Bridgetown JV farm-in and navigating an unsolicited takeover offer.